LEGN vs. GSK
LEGN (Legend Biotech Corporation) and GSK (GSK plc) are both stocks. Both are in the Healthcare sector — LEGN in Biotechnology, GSK in Drug Manufacturers - General. Over the past 5 years, LEGN returned -7.67%/yr vs 5.23%/yr for GSK. At a 0.20 correlation, their price movements are largely independent.
Performance
LEGN vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LEGN achieves a 24.56% return, which is significantly higher than GSK's 9.35% return.
LEGN
- 1D
- -1.10%
- 1M
- -24.51%
- 6M
- 14.75%
- YTD
- 24.56%
- 1Y
- -30.49%
- 3Y*
- -27.72%
- 5Y*
- -7.67%
- 10Y*
- —
GSK
- 1D
- 0.59%
- 1M
- -0.49%
- 6M
- 6.42%
- YTD
- 9.35%
- 1Y
- 42.87%
- 3Y*
- 20.25%
- 5Y*
- 5.23%
- 10Y*
- 4.38%
LEGN vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
LEGN Legend Biotech Corporation | 24.56% | -33.19% | -45.92% | 20.53% | 7.10% | 65.52% | -23.89% |
GSK GSK plc | 9.35% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -9.46% |
Correlation
The correlation between LEGN and GSK is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.22 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Jun 5, 2020 | 0.20 |
Fundamentals
LEGN:
$5.01B
GSK:
$105.71B
LEGN:
-$1.63
GSK:
£2.85
LEGN:
3.65
GSK:
2.45
LEGN:
2.59
GSK:
3.40
LEGN:
$1.14B
GSK:
£32.78B
LEGN:
$611.63M
GSK:
£23.87B
LEGN:
-$186.04M
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LEGN vs. GSK — Risk / Return Rank
LEGN
GSK
LEGN vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Legend Biotech Corporation (LEGN) and GSK plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LEGN | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.86 | ||
| Sortino ratioReturn per unit of downside risk | -2.47 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.25 | -0.30 |
| Calmar ratioReturn relative to maximum drawdown | -0.51 | 2.06 | -2.57 |
| Martin ratioReturn relative to average drawdown | -0.78 | 4.87 | -5.66 |
Loading charts...
Drawdowns
LEGN vs. GSK - Drawdown Comparison
The maximum LEGN drawdown since its inception was -78.24%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for LEGN and GSK.
Loading charts...
Drawdown Indicators
| LEGN | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.24% | -55.70% | -22.54% |
Max Drawdown (1Y)Largest decline over 1 year | -62.43% | -18.63% | -43.80% |
Max Drawdown (3Y)Largest decline over 3 years | -78.24% | -28.46% | -49.78% |
Max Drawdown (5Y)Largest decline over 5 years | -78.24% | -50.10% | -28.14% |
Max Drawdown (10Y)Largest decline over 10 years | — | -50.10% | — |
Current DrawdownCurrent decline from peak | -64.60% | -12.35% | -52.25% |
Average DrawdownAverage peak-to-trough decline | -31.78% | -18.86% | -12.92% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 40.62% | 7.96% | +32.66% |
Volatility
LEGN vs. GSK - Volatility Comparison
Legend Biotech Corporation (LEGN) has a higher volatility of 22.64% compared to GSK plc (GSK) at 8.25%. This indicates that LEGN's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LEGN | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.64% | 8.25% | +14.39% |
Volatility (6M)Calculated over the trailing 6-month period | 60.26% | 19.50% | +40.76% |
Volatility (1Y)Calculated over the trailing 1-year period | 70.14% | 27.25% | +42.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 56.80% | 25.25% | +31.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.99% | 22.89% | +33.10% |
Dividends
LEGN vs. GSK - Dividend Comparison
LEGN has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.28%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GSK plc | 3.28% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
LEGN Legend Biotech Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
LEGN vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Legend Biotech Corporation and GSK plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LEGN vs. GSK - Profitability Comparison
LEGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported a gross profit of 113.94M and revenue of 306.01M. Therefore, the gross margin over that period was 37.2%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, GSK plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
LEGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported an operating income of -47.04M and revenue of 306.01M, resulting in an operating margin of -15.4%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, GSK plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
LEGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Legend Biotech Corporation reported a net income of -54.46M and revenue of 306.01M, resulting in a net margin of -17.8%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, GSK plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
LEGN and GSK have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LEGN has higher volatility (22.64%) compared to GSK (8.25%). In terms of maximum drawdown, LEGN dropped -78.24% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.41 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LEGN and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer